|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
CEL-SCI CORPORATION RELEASES LETTER TO SHAREHOLDERS
Dear Fellow Shareholders:
With the start of the New Year, I thought it would be helpful to provide you with a review of the progress made in our Multikine cancer Phase III clinical trial during the last year and our thoughts for the future of Multikine.
During 2011, we made great operational progress in bringing our investigational cancer drug Multikine
| 1st Jan change | Capi. | |
|---|---|---|
| +0.85% | 92.38B | |
| -3.03% | 37.9B | |
| -10.46% | 33.73B | |
| +74.71% | 27.98B | |
| -13.39% | 15.86B | |
| -1.08% | 13.97B | |
| -11.15% | 11.67B | |
| +169.04% | 10.17B | |
| -50.19% | 10.04B |
CEL-SCI CORPORATION 
By 